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Abstract
Integrins, which are transmembrane receptors for extracellular matrix proteins, play a key role in
cell survival, proliferation, migration, gene expression, and activation of growth factor receptors.
Their functions and expression are deregulated in several types of cancer, including prostate
cancer. In this article, we review the role of integrins in prostate cancer progression and their
potential as therapeutic targets.
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Introduction
Prostate cancer develops through a series of defined
states: prostatic intraepithelial neoplasia (PIN), high-
grade PIN lesions, invasive cancer, and an andro-
gen-independent state (Scher & Heller 2000, Culig
& Bartsch 2006, Dehm & Tindall 2006). These
defined states arise through multiple alterations in
normal cell functions (Mimeault & Batra 2006).
Among the alterations described in prostate cancer
are abnormal expression and functions of integrins
and of their extracellular matrix (ECM) ligands
(Boudreau & Bissell 1998, Fornaro et al. 2001).
The resulting abnormal cellular interactions with
the ECM promote cell proliferation, migration, and
differentiation and contribute to cancer progression
through the above-described states (Boudreau &
Bissell 1998, Fornaro et al. 2001, Knudsen &
Miranti 2006). We review here several studies
describing aberrations in the normal expression and
functions of integrins in prostate cancer, specifically
those that are likely to be relevant to the progression
of this disease. Due to space constraints, we will not
be able to review all the in vitro studies published
in this area of research.
Integrin deregulation in prostate cancer
In prostate cancer, tumor cells express an abnormal
integrin repertoire and are surrounded by a markedly
aberrant ECM. These changes have profound con-
sequences, given the ability of each integrin to regulate
specific cell functions. At this time, 24 members of the
integrin family, 18 a and 8 b subunits have been
described; for a detailed description of the 24 members
and for their ECM ligands, the reader should refer to
Hynes 2002 and Alam et al. 2007.
Several studies report deregulation of integrin
expression as prostate cancer progresses to an
advanced stage (Fornaro et al. 2001, Edlund et al.
2004, Knudsen &Miranti 2006; Table 1). Most a and b
subunits have been shown to be downregulated in
prostate cancer.
Among the a subunits, several reports show that the
a3, a4, a5, a7, and av are downregulated, aIIb is
upregulated and a2 and a6 are aberrantly expressed as
discussed below, whereas there are no reports on the
remaining subunits (Table 1). A unique expression
pattern has been shown for a2, which is downregulated
in prostate cancer but upregulated in lymph node
metastases when compared with primary lesions
(Bonkhoff et al. 1993). An extensive analysis of a6
expression in prostate cancer has been reported;
a6 expression is maintained in prostate neoplasm,
but its expression becomes more intense and its density
at sites of contact with the basement membrane
diminishes with increasing histologic grade (Bonkhoff
et al. 1993).
Among the b subunits, b1, b3, and b6 are upregulated
in human prostate cancer. b1C and b4 are down-
regulated, whereas no reports are available for b5, b7,
and b8 (Table 1).
Five b1 variant subunits, b1A, b1B, b1C, b1C-2 and b1D,
generated by alternative splicing, have been described.
Two variants, b1C and b1A, have been shown to be
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expressed in prostatic epithelium. b1C is shown to be
expressed at both protein and mRNA levels in normal
prostatic epithelial cells, but is markedly downregulated
in adenocarcinoma (Fornaro et al. 1996, 1998, 1999,
Perlino et al. 2000).b1A has been found to be consistently
upregulated in human prostate cancer (Knox et al. 1994,
Murant et al. 1997,Goel et al. 2007) aswell as in amouse
model designated TRAMP (transgenic adenocarcinoma
of mouse prostate) (Goel et al. 2005). Since b1A
associates with many a integrins and a2 and a6 are
elevated in prostate cancer, it is conceivable that b1Awill
be present predominantly as a2b1 and/or a6b1 hetero-
dimeric complexes (Bonkhoff et al. 1993, Fornaro et al.
2001, Alam et al. 2007). The finding that the expression
of the b1A integrin variant is upregulated and is necessary
for cells to be able to grow in an anchorage-independent
manner, point to the important role that b1A integrin may
have during prostate cancer progression and will be
helpful in formulating new therapeutic strategies (Goel
et al. 2005). Recently, increased levels of b1 and its
ligand, fibronectin, have been shown to be associated
with decreased survival of breast cancer patients (Yao
et al. 2007), but this finding has not been reported in
prostate cancer.
Upregulation of b3 and b6 integrin variants has been
described. Zheng et al. (1999) used human prostate
cancer cells isolated from 16 surgical specimens, to
show that these cells express avb3, whereas normal
prostate epithelial cells do not. Similarly, avb6 (Azare
et al. 2007, Li et al. 2007a) and the truncated aIIb
integrin variant (Trikha et al. 1998a) were found to be
expressed in adenocarcinoma.
The b1, b3, and b6 integrin subunits are known to
localize in focal contacts and to mediate spreading and
cytoskeletal rearrangements in normal cells (Hynes
2002, Alam et al. 2007). However, when we either
downregulated or upregulated these subunits by siRNA
or ectopic expression analysis, we showed that cancer
cell spreading was not affected. These results demon-
strate that the ability of b1, b3, and b6 subunits to
promote cancer progression is independent of cell
spreading.
Table 1 Integrin deregulation in human prostate cancer
Sample; method Deregulated expression References
a Subunit
a2 Tissue specimens; IHC Downregulated in adenocarcinoma
a;
upregulated in metastases
Bonkhoff et al. (1993) and
Nagle et al. (1994)
a3, a4, a5 Tissue specimens; IHC Downregulated in adenocarcinoma Nagle et al. 1994
a6 Tissue specimens; IHC, TEM Polarized distribution in benign,
less polarized in HGPIN, not
Bonkhoff et al. (1993), Knox et al.
(1994) and Nagle et al. (1995)
polarized in lymph node meta-
stases; upregulated in metastases
a7 Tissue specimens; IHC,
sequencing of genomic
DNAs and cDNAs
Downregulated in adenocarcinoma;
also mutated in adenocarcinoma
and recurrent adenocarcinoma
Ren et al. (2007)
aIIb (truncated) Tissue specimens; IHC Expressed in adenocarcinoma;
absent in normal tissue
Trikha et al. (1998a,b)
b Subunit
b1 Tissue specimens; IHC Upregulated in adenocarcinoma;
redistributed with progression
Knox et al. (1994), Murant et al.
(1997) and Goel et al. (2007)
b1C Tissue specimens; IHC Downregulated in adenocarcinoma
b Fornaro et al. (1996, 1998, 1999)
and Perlino et al. (2000)
b3 Freshly isolated cells and primary
cultures, tissue specimens;
FACS, Immunoblotting, IHC
Expressed in adenocarcinoma and
metastatic lesions; absent in
normal cells
Zheng et al. (1999)
b4 Tissue specimens; IHC Downregulated in adenocarcinoma
c Nagle et al. (1995), Allen et al.
(1998) and Davis et al. (2001)
b6 Tissue specimens; IHC Upregulated in adenocarcinoma and
metastases; absent in normal cells
Li et al. (2007a)
Studies performed using cell lines are not included. IHC, immunohistochemistry; TEM, transmission electron microscopy; FACS,
fluorescence-activated cell sorting.
a
a2 was found to be downregulated in 70% cases with grade II and III tumors.
b
b1C downregulation was observed regardless of the tumor Gleason grade (grade II to V).
c
b4 downregulation was observed regardless of the tumor Gleason grade (grade II to V).
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Expression of b3 and b1 subunits activates specific
signaling pathways and support distinct cancer cell
functions. We have discovered that b3 is uniquely
required in cancer cells for increasing cdc2 levels as
well as cdc2 kinase activity. These effects are specific
for b3 and are not observed for b6, although both
subunits associate with the same a subunit, av. Higher
levels of cdc2 result in increased cell migration
mediated by specific association of cdc2 with cyclin
B2 and phosphorylation of caldesmon, a substrate of
cdc2. We also demonstrate that cdc2 and caldesmon
are localized in the membrane ruffles of motile cells.
These results show that cdc2 acts as a downstream
effector of the avb3 integrin and that it promotes cancer
cell migration (Manes et al. 2003). In contrast, b1
integrin expression did not increase cancer cell motility
or cdc2 levels; it appeared, predominantly, to modulate
cell proliferation and survival (Manes et al. 2003, Goel
et al. 2005). Analysis of the mechanism by which b1
may promote tumor growth in vivo shows that b1
is uniquely required in cancer cells for localization,
expression, and function of a surface receptor – insulin-
like growth factor (IGF) type 1 receptor (IGF-IR)
which is known to support cancer cell proliferation
and survival (Goel et al. 2004, 2005). The mechanism
proposed for the control of b1 integrin on IGF-IR
activity involves the recruitment of specific adaptors to
the plasma membrane by b1, thus increasing the
concentration of specific adaptors proximal to the
growth factor receptor (Goel et al. 2004). Evidence is
provided in this study that the b1 cytodomain plays an
important role in mediating b1 integrin association
with either IRS-1 or Grb2-associated binder1 (Gab1)/
SH2-containing protein-tyrosine phosphate 2 (Shp2),
downstream effectors of IGF-IR: specifically, b1A
associates with IRS-1 and b1C with Gab1/Shp2 (Goel
et al. 2004, 2005). In conclusion, the b3 and b1
integrins facilitate activation of selective signaling
pathways that support cancer progression.
Additional evidence indicates that PTEN, a tumor
suppressor frequently deleted or mutated in prostate
cancer (Li et al. 1997, Steck et al. 1997), may play a
role in the regulation of cell migration on integrin
substrates (Tamura et al. 1998, Wu et al. 2007). The
mechanism through which it regulates cell migration is
not known, although it is likely to utilize PTEN
phosphatase activity, which has the ability to depho-
sphorylate inositol phospholipids such as PIP3 and, as
a consequence, to negatively regulate activation of a
modulator of motility on integrin substrates, AKT
(Alam et al. 2007).
Overall, these findings indicate that the expression
of selective integrin subunits is deregulated during
prostate cancer progression and that these subunits are
potential diagnostic markers in prostate cancer.
In vivo integrin functions in prostate
cancer
As modulators of cell survival, migration, invasion,
and angiogenesis (Parise et al. 2000, Fornaro et al.
2001, Tantivejkul et al. 2004, Moschos et al. 2007)
integrins promote progression of many types of cancer
including prostate cancer (Fornaro et al. 2001).
Preclinical studies (Park et al. 2006, Van Aarsen
et al. 2008, Cariati et al. 2008) that have utilized
inhibitory antibodies, RGD peptides or siRNA to
block integrin functions or expression have shown
promising results. We review below the evidence
supporting a role for integrins in prostate cancer
growth and metastasis in vivo.
Tumor growth and metastasis
Primary tumor growth has been shown to be affected
by integrin expression. Expression of the b1 cyto-
plasmic variant, b1C, which is downregulated in
prostate cancer, completely prevents tumor growth by
inhibiting IGF-IR signaling (Goel et al. 2004). It has
also been reported that the expression of a7 in prostate
cancer cells injected subcutaneously in SCID mice
suppresses tumor growth (Ren et al. 2007). This
observation is relevant to the human disease as analysis
of a7 in human prostate cancer reveals that a7 is
downregulated in this type of cancer and is mutated in
57% of prostate cancers; in addition, mutations in this
subunit are associated with increased cancer recurrence
(Ren et al. 2007). Pawar et al. (2007) show that growth
of tumors treated with fractionated doses of irradiation
(3 Gy!10 days) is inhibited in PC3 cells expressing a
mutated non-cleavable form of a6 integrin. Thus,
blocking integrin cleavage in vivo may be efficacious
for increasing responsiveness to irradiation of pro-
metastatic human prostate cancer.
The metastatic process is likely to be dependent on
the ability of cancer cells to migrate and invade, but it
is also dependent on the ability of these cells to grow in
distant sites (Fornaro et al. 2001, Felding-Habermann
2003). All these functions are mediated by integrins.
Early studies using PC3 and DU145 cells, both of
which express integrin aIIbb3, suggest a role for aIIbb3
in prostate cancer metastasis. These cell lines,
implanted subcutaneously or intraprostatically into
SCID mice, prove tumorigenic, but only DU145 cells
injected intraprostatically metastasized. An analysis
performed on the cells described above using an
Endocrine-Related Cancer (2008) 15 657–664
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antibody to aIIbb3 shows a higher expression of aIIbb3
in DU145 tumor cells isolated from the prostate when
compared with DU145 tumor cells from the subcutis.
These data suggest a role for aIIbb3 in the metastatic
progression of prostatic adenocarcinoma (Trikha et al.
1998b). De et al. (2003) use secreted protein acidic and
rich in cysteine (SPARC)-deficient mice and show that
SPARC selectively supports the migration of highly
metastatic as opposed to less metastatic cancer cell
lines to bone in an avb3- and avb5-dependent manner.
It should be stressed that ECM proteins are routinely
cleaved and their fragments bind integrins (Giannelli
et al. 1997, Hynes 2002). The relative ratio of matrix
metalloproteinases, cell surface proteases, such as
hepsin (Klezovitch et al. 2004) which is upregulated
in prostate cancer, and protease inhibitors such as
maspin known to be a metastasis suppressor (Li et al.
2007a,b, Luo et al. 2007), contribute to ECM protein
cleavage. This allows tumor cells to invade connective
tissues and travel out of the vasculature to distant sites
(Zucker et al. 2000).
Bone is the most frequent metastatic site for this
disease. Bisanz et al. (2005) illustrate a positive role
for av integrins on prostate tumor survival in the bone.
Analysis of human prostate cancer bone xenografts
shows that intratumoral administration of liposome-
encapsulated human av-siRNAs significantly inhibits
the growth of PC3 tumors in bone and increases
apoptosis of prostate tumor cells. Further studies,
implicating integrin av in prostate cancer metastasis in
bone, by McCabe et al. (2007) indicate that expression
of fully functional avb3 enable tumor growth in bone
whereas inactive or constitutively active mutants do
not. They demonstrate that avb3 integrin activation on
tumor cells is essential for the recognition of key bone-
specific matrix proteins. These data suggest that the
avb3 integrin modulates prostate cancer growth in
distant metastasis. Other studies implicate a2b1 as a
possible modulator of prostate cancer metastasis to
bone matrix proteins. Hall et al. (2006) tested whether
prostate cancer bone metastasis is mediated by binding
to type I collagen, an abundant bone protein that binds
a2b1. To directly test this, a collagen-binding variant of
human LNCaP cells, LNCaPcol, was created and
injected into the tibia of nude mice. After 9 weeks,
53% of mice injected with LNCaPcol develop bone
tumors whereas none of the mice injected with parental
LNCaP had signs of bone lesions.
Finally, it should be noted that adhesion of highly
metastatic prostate cancer cells to bone marrow
endothelial cells require additional ECM components
that do not bind integrins. Among others, a matrix of a
secreted glycosaminoglycan component of the ECM,
hyaluronan (HA), is required to provide specific
adhesion of highly metastatic prostate cancer cells to
bone marrow endothelial cells (Simpson et al. 2002a).
This molecule may act through regulation of cancer
cell growth (Simpson et al. 2002b).
Tumor angiogenesis
Angiogenesis, a process critical for tumor formation and
growth (Nicholson & Theodorescu 2004, Jimenez et al.
2006, Sakamoto et al. 2008), is regulated by integrin
functions (Hynes 2007). avb3 and avb5, by using a
crosstalk with growth factor signaling pathways (Alam
et al. 2007), regulate angiogenesis. Sun et al. (2007) have
evaluated the efficacy of a new camptothecin conjugate,
JF-10-81, an anti-angiogenic agent, in a prostate cancer
mouse model. JF-10-81 blocks cancer cell adhesion
in vivo and angiogenesis in C57B1/N mice and reduces
expression of avb3 and avb5 on PC3 cells which implies
an inhibitory effect on angiogenesis through anavb3- and
avb5-dependent mechanism. A study that analyzes a
knock-in mouse expressing a mutant b3 that cannot
undergo tyrosine phosphorylation shows that b3-
deficient mice have impaired capillary formation in
response to VEGF stimulation, and thus form smaller
prostate tumors than their wild-type counterparts. These
observations highlight the role of vascular avb3 in
prostate cancer through modulation of angiogenesis
(Mahabeleshwar et al. 2006). Finally, a promising
avenue is presented by a study showing that the treatment
of a PC3 xenograft with an avb3 antagonist (S247, a
cyclic RGD peptidomimetic) in combination with
radiation, leads to enhanced anti-angiogenic and anti-
tumor effects when compared with either therapy alone
(Abdollahi et al. 2005).
The use of integrin inhibitors is likely to affect both
cancer cell survival and angiogenesis since integrins
are expressed by tumor cells as well as by endothelial
cells. Although it is hard to discriminate between an
effect on tumor growth and an effect on angiogenesis, a
maximal response of these inhibitors can be predicted
when the targeted integrin is expressed by both tumor
and endothelial cells.
These preclinical studies which take advantage of
the available mechanistic investigations, have
prompted several clinical studies (described below),
aimed at identifying novel molecular strategies to
block prostate cancer progression.
Integrin inhibitors in clinical trials
Clinical trials that evaluate the effect of integrin
antagonists as prostate cancer therapeutics are
H L Goel et al.: Integrins and prostate cancer
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ongoing. Available reports at this time indicate that the
av integrins are promising therapeutic targets in
prostate cancer. Two clinical trials using Cilengitide,
a cyclic Arg-Gly-Asp peptide that inhibits avb3 and
avb5 (Beekman et al. 2006), an antagonist of av
integrins, are in progress. Cilengitide is being
evaluated in two Phase II clinical trials. In one study
(NCI 6735), one dose of 2000 mg given intravenously
twice weekly is being evaluated in men with androgen-
independent prostate cancer and non-metastatic
disease. In another study, (NCI 6372), two dose levels
of Cilengitide, 500 and 2000 mg, are administered
twice weekly in men with androgen-independent
metastatic prostate cancer (Beekman et al. 2006).
Antibodies to av integrins are also being evaluated in
two clinical trials. The first utilizes CNTO 95, a
monoclonal antibody that inhibits av integrins and
blocks tumor growth (Chen et al. 2007). In Phase I,
CNTO 95 (10 mg/kg, once a week) in combination
with standard drugs docetaxel (75 mg/m2, every 3
weeks) and prednisone (twice a day) appears to be well
tolerated in hormone refractory prostate cancer patients
(Chu et al. 2007). A Phase II clinical trial
(NCT00537381) is also in progress with CNTO 95
(10 mg/kg, once a week) in combination with
docetaxel (75 mg/m2, every 3 weeks) and prednisone
(twice a day) in metastatic hormone refractory prostate
cancer patients. The second trial utilizes MEDI-522, a
humanized monoclonal IgG1 antibody directed against
the avb3 integrin. MEDI-522 blocks the binding of
ligands, such as vitronectin, to avb3 integrin (McNeel
et al. 2005). A Phase II, randomized, open-label, two-
arm, multicenter study of MEDI-522, in combination
with docetaxel, prednisone, and zoledronic acid in the
treatment of patients with metastatic androgen-inde-
pendent prostate cancer (NCT00072930) is ongoing.
Results from these studies will pave the way to new and
improved strategies toprevent prostate cancer in humans.
Conclusions
Prostate cancer accounts for a significant cancer
burden in the USA, where it is projected to result in
over 28 660 deaths and more than 186 320 new cases in
2008 (Jemal et al. 2008). While substantial advances
have been made in diagnosing and treating this
disease, the molecular mechanisms that promote
prostate cancer progression remain to be fully
investigated (Pomerantz & Kantoff 2007). The studies
reviewed here show that prostate cancer progression
has been correlated with expression of specific integrin
subunits and is influenced by deregulation of selective
subunits, which then activate distinct signaling
pathways (Fornaro et al. 2001). Although the
molecular pathways by which integrins contribute to
cancer progression need to be fully elucidated,
designing new therapeutic approaches for prostate
cancer based on inhibiting integrin expression, Ligand
binding or downstream signaling is likely to be a
successful strategy.
Several questions remain to be answered in this under-
investigated area of research. The mechanisms by which
integrins are regulated need to be characterized by
focusing on modulators of integrin expression. Yet
another promising avenue of research is to elucidate the
role of integrins in promoting proliferation of prostate
cancer stem cells, in particular, a2b1 appears to be
interesting since it is highly expressed in these cells
(Collins et al. 2005, Mimeault et al. 2007). Finally, an
under-investigated area in prostate cancer research is the
cross talk between bone microenvironment and metas-
tasis (Mohla 2004), to which the interactions between
integrins and their ECM ligands are likely to contribute
significantly. Since integrins mediate the interactions
between tumor cells and bone microenvironment and
facilitate growth in bone, a potential application of the
use of integrin inhibitors is to prevent prostate cancer
bone lesions (Waltregny et al. 2000, Pecheur et al. 2002,
Karadag et al. 2004, Hall et al. 2006). These lesions are
osteoblastic or osteolytic and are frequently detected in
prostate cancer patients (over 80% of prostate cancer
patients have established bone metastasis at autopsy
(Koeneman et al. 1999)). A recent study has shown
that the avb3 integrin promotes bone gain mediated
by prostate cancer cells that metastatize to the bone
and point to avb3 as a potential therapeutic target to
block prostate cancer osteoblastic lesions (Keller
&Brown 2004,McCabe et al. 2007). Besides therapeutic
applications, other uses of integrin inhibitors are in
the area of imaging and specific delivery of a drug
to cancer cells (Chen et al. 2001, Moschos et al. 2007,
Li et al. 2008).
In conclusion, these investigations indicate that the
clinical use of integrin inhibitors is likely to be a
successful strategy to prevent all stages of cancer
progression from tumor growth to metastasis.
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